Table 2 Pharmacological routine type preferences for hip and knee arthroplasty in Study 1 and Study 2
Study 1 (N = 221) | Study 2 (N = 431) | |||
|---|---|---|---|---|
Hip n = 197 (%) | Knee n = 216 (%) | Hip n = 384 (%) | Knees n = 427 (%) | |
Anticoagulant-only | 144 (73.1) | 161 (74.5) | 155 (40.4) | 176 (41.2) |
Staged-supply | 16 (8.1) | 19 (8.8) | 76 (19.8) | 86 (20.1) |
Risk-stratification | 9 (4.6) | 10 (4.6) | 143 (37.2) | 156 (36.5) |
Routine patients: Aspirin only High Risk patients: Anticoagulant only | 2 (1.0) | 2 (0.9) | 103 (26.8) | 116 (27.2) |
Routine patients: Anticoagulant, then aspirin High Risk patients: Extended anticoagulant therapy | 1 (0.5) | 1 (0.5) | 24 (6.3) | 28 (6.6) |
Routine patients: Anticoagulant as inpatient only High Risk patients: Extended anticoagulant therapy | – | – | 6 (1.6) | 6 (1.4) |
Routine patients: Aspirin only High Risk patients: Anticoagulant, then aspirin | – | – | 1 (0.3) | 1 (0.2) |
Protocol unclear, however employs anticoagulants and aspirin in a risk-stratification protocol. | 6 (3.0) | 7 (3.2) | 9 (2.3) | 5 (1.2) |
Aspirin-only | 25 (12.7) | 23 (10.6) | 7 (1.8) | 6 (1.4) |
Miscellaneousa | – | – | 2 (0.5) | 2 (0.5) |
Thromboprophylaxis protocol not reported | 3 (1.3) | 3 (1.4) | 1 (0.3) | 1 (0.2) |